Pyxis Oncology, Inc.

NASDAQ:PYXS

Biotechnology

Healthcare
$1.41 +5.53%

+$0.11 today

Market cap
$168.65M
Beta
1.43
P/E (TTM)
-1.6
EPS (TTM)
-$1.29
52W Low $0.97High $5.55

Volume 0.75M

Average 0.50M

PYXS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Pyxis Oncology, Inc.NASDAQ: PYXS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $3.63M a year earlier. Trailing-twelve-month stock-based compensation was $8.17M. Over 3 fiscal years it compounded at -9.2% a year.

Context

  • Stock-based compensation amounted to 85.2% of revenue in FY2025, up 5.0 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.04M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$11.8M-8.8% YoY
LTMMar 2026
$8.17M-33.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-8.8%——
3-year CAGR-9.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.8M USD
Year-over-year change
-8.8%
4-year CAGR
+16.3%

Stock-Based Compensation vs competitors

How PYXS compares with its peers on the latest reported figures

  • PYXS's LTM Mar 2026 stock-based compensation of $8.17M is the 8th largest of the 10 companies compared; the peer median is $11.32M.
  • Its year-over-year change of -33.3% is the 7th highest of 10, against a peer median of -32.8%.
  • Stock-based compensation amounts to 59.0% of revenue for PYXS, versus a peer median of 68.4%.
PYXS Competitors Peer median
Stock-Based Compensation for PYXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$17.5M -62.1%-23.7%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M -32.9%-11.7%22.8%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$13.6M -8.6%+16.5%37.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M -28.1%+4.4%5116.0%
ZURAZura Bio LimitedLTM Mar 2026$11.32M -37.2%+233.0%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M -32.8%+2.7%99.6%
HUMAHumacyte, Inc.LTM Mar 2026$10.44M +45.6%+16.4%517.7%
PYXSPyxis Oncology, Inc.LTM Mar 2026$8.17M -33.3%-9.2%59.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M +42.2%—26.1%
IMRXImmuneering CorporationLTM Mar 2026$1.52M -69.5%——
Peer median (excluding PYXS) $11.32M-32.8%+4.4%68.4%

Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(75.98M)(120.72M)(73.79M)(77.33M)(79.62M)
Depreciation & Amortization647K709K1.93M2.98M4.51M
Deferred Income Tax6.28M0000
Stock-Based Compensation6.44M15.76M16.95M12.95M11.8M
Change in Working Capital6.68M4.5M(11.66M)(11.82M)1.94M
Accounts Receivables00000
Inventory00000
Accounts Payables4.64M(8.33M)(3.51M)1.2M6.03M
Other Working Capital2.03M12.83M(8.16M)(13.02M)(4.08M)
Other Non-Cash Items20.6M10.41M(4.13M)15.56M(2.14M)
Operating Cash Flow(35.33M)(89.34M)(70.71M)(57.67M)(63.5M)
Capital Expenditures(540K)(6.4M)(6.73M)(237K)(9K)
Acquisitions (Net)(50K)06.66M00
Purchases of Investments(50K)0(196.83M)(160.12M)(107.01M)
Sales of Investments50.05K092.05M168.51M165.87M
Other Investing Activities(50)0000
Investing Cash Flow(590K)(6.4M)(104.85M)8.16M58.86M
Debt Repayment00000
Common Stock Issued152.3M06.12M59.05M742K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities167K183K(193K)280K(148K)
Financing Cash Flow304.04M183K5.93M59.33M594K
Effect of Forex Changes00000
Net Change in Cash268.13M(95.55M)(169.63M)9.81M(4.05M)
Free Cash Flow(35.87M)(95.73M)(77.44M)(57.91M)(63.51M)

Pyxis Oncology, Inc.

NASDAQ:PYXS

Intrinsic Alpha fair value

Locked

Current Price

$1.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.